Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Aug;54(8):1807-1813.
doi: 10.1007/s11255-022-03230-4. Epub 2022 May 16.

Testosterone kinetics on hypogonadal men under clomiphene

Élcio Dias Silva #  1 , Maurício Moreira da Silva Jr #  1 , Tomas B C Moretti  1 , Danilo L Andrade  1 , Natália Dalsenter Avilez  1 , Leonardo O Reis  2
Affiliations
Clinical Trial

Testosterone kinetics on hypogonadal men under clomiphene

Élcio Dias Silva et al. Int Urol Nephrol. 2022 Aug.

Abstract

Objective: To evaluate total testosterone (TT) kinetics and its predictors 6 months after the discontinuation of clomiphene citrate (CC) in patients with hypogonadism.

Materials and methods: Consecutive patients with normal testicles and male hypogonadism defined by TT < 300 ng/dl in the presence of signs or symptoms according to the previous consensus were prospectively evaluated in a urologic outpatient clinic by TT levels at baseline (T0), after a daily dose of 50 mg CC for 40 days (T1), and after the washout period of 6 months of CC discontinuation (T2).

Results: Among 75 patients, mean age 56.8 years, testosterone at T1 > 300 ng/dl was achieved by 69 (92%), 450-600 ng/dl by 32 (42.6%), and > 600 ng/dl by 27 (36.0%). 18 subjects (24%) maintained asymptomatic and TT levels over 300 ng/dl at T2. Age negatively related to testosterone response and T1 response > 810 ng/dl predicts a median gain of 166.5 ng/dl at 6 months of CC discontinuation.

Conclusions: CC is a compelling option to treat male hypogonadism, although a chronic treatment is needed in most patients. About one in every four patients respond to a CC short trial to "reboot" the physiology. Further understanding of TT kinetics in these patients in the long term is warranted.

Keywords: Clomiphene citrate; Hypogonadism; Kinetics; Male; SERM; Testosterone.

PubMed Disclaimer

References

    1. Krzastek SC, Smith RP (2020) Non-testosterone management of male hypogonadism: an examination of the existing literature. Transl Androl Urol 9(Suppl 2):S160–S170 - DOI
    1. Keihani S, Wright LN, Alder NJ et al (2020) Baseline gonadotropin levels and testosterone response in hypogonadal men treated with clomiphene citrate. Urology 142:119–124 - DOI
    1. Wheeler KM, Sharma D, Kavoussi PK, Smith RP, Costabile R (2019) Clomiphene citrate for the treatment of hypogonadism. Sex Med Rev 7(2):272–276 - DOI
    1. Marconi M, Souper R, Hartmann J, Alvarez M, Fuentes I, Guarda FJ (2016) Clomiphene citrate treatment for late-onset hypogonadism: rise and fall. Int Braz J Urol 42(6):1190–1194 - DOI
    1. Masterson JM, Cohen J, Blachman-Braun R, Machen GL, Sandlow J, Ramasamy R (2020) Pre-treatment estradiol does not predict testosterone response to clomiphene citrate. Transl Androl Urol 9(2):609–613 - DOI

Publication types

LinkOut - more resources